Allele-Specific p53 Mutant Reactivation

265Citations
Citations of this article
315Readers
Mendeley users who have this article in their library.

This article is free to access.

Abstract

Rescuing the function of mutant p53 protein is an attractive cancer therapeutic strategy. Using the National Cancer Institute's anticancer drug screen data, we identified two compounds from the thiosemicarbazone family that manifest increased growth inhibitory activity in mutant p53 cells, particularly for the p53R175 mutant. Mechanistic studies reveal that NSC319726 restores WT structure and function to the p53R175 mutant. This compound kills p53R172H knockin mice with extensive apoptosis and inhibits xenograft tumor growth in a 175-allele-specific mutant p53-dependent manner. This activity depends upon the zinc ion chelating properties of the compound as well as redox changes. These data identify NSC319726 as a p53R175 mutant reactivator and as a lead compound for p53-targeted drug development. © 2012 Elsevier Inc.

Cite

CITATION STYLE

APA

Yu, X., Vazquez, A., Levine, A. J., & Carpizo, D. R. (2012). Allele-Specific p53 Mutant Reactivation. Cancer Cell, 21(5), 614–625. https://doi.org/10.1016/j.ccr.2012.03.042

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free